Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17,077 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, Chen Y, Babbar A, Firdaus SJ, Darjania L, Feng J, Chen JH, Li S, Li S, Long YO, Thach C, Liu Y, Zarieh A, Ely T, Kucharski JM, Kessler LV, Wu T, Yu K, Wang Y, Yao Y, Deng X, Zarrinkar PP, Brehmer D, Dhanak D, Lorenzi MV, Hu-Lowe D, Patricelli MP, Ren P, Liu Y. Janes MR, et al. Among authors: feng j. Cell. 2018 Jan 25;172(3):578-589.e17. doi: 10.1016/j.cell.2018.01.006. Cell. 2018. PMID: 29373830 Free article.
CAR-T Cell Therapy: Advances in Kidney-Related Diseases.
Wu L, Feng Y, Huang Y, Feng J, Hu Y, Huang H. Wu L, et al. Among authors: feng j. Kidney Dis (Basel). 2024 Jan 10;10(2):143-152. doi: 10.1159/000536194. eCollection 2024 Apr. Kidney Dis (Basel). 2024. PMID: 38751795 Free PMC article. Review.
Expert consensus on the clinical application of immunotherapy in breast cancer: 2024.
Wang K, Yang J, Wang B, Liu Q, Wang X, Yin Y, Wang H, Wang S, Hao C, Hao X, Liu Y, Jiang Z; Chinese Society of Clinical Oncology Breast Cancer Committee*; Chinese Society of Clinical Oncology Breast Cancer Committee. Wang K, et al. Transl Breast Cancer Res. 2024 Apr 29;5:9. doi: 10.21037/tbcr-24-15. eCollection 2024. Transl Breast Cancer Res. 2024. PMID: 38751677 Free PMC article. Review.
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study.
Wang T, Zhang P, Di L, Wang X, Yang J, Tong Z, Liu J, Feng J, Liu D, Yu Q, Liu Y, Yu H, Jiang Z. Wang T, et al. Among authors: feng j. Transl Breast Cancer Res. 2022 Apr 30;3:15. doi: 10.21037/tbcr-21-42. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751509 Free PMC article.
Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine vs. lapatinib plus capecitabine in Chinese patients with HER2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy.
Wang X, Li W, Yin Y, Tong Z, Zhang Q, Zheng H, Shao Z, Li H, Yang J, Feng J, Wu F, Lamour F, Restuccia E, Jiang Z. Wang X, et al. Among authors: feng j. Transl Breast Cancer Res. 2023 Jan 31;4:3. doi: 10.21037/tbcr-23-2. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751488 Free PMC article.
17,077 results
You have reached the last available page of results. Please see the User Guide for more information.